Effects of memantine and galantamine on cognitive performance in aged rhesus macaques

  title={Effects of memantine and galantamine on cognitive performance in aged rhesus macaques},
  author={Jay S Schneider and Elsa Y. Pioli and Yang Jianzhong and Qin Li and Erwan B{\'e}zard},
  journal={Neurobiology of Aging},
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus)
The results indicate that two widely used drugs for mitigating cognitive deficits in AD were partially effective in sleep deprived mouse lemurs, which further support the translational potential of this animal model.
Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia
  • M. Koola
  • Psychology, Medicine
    Molecular Neuropsychiatry
  • 2018
The objective of this article is to critically dissect the published randomized controlled trials with galantamine and memantine for CIAS to highlight the efficacy signal and suggest a “low-risk high-gain” approach that could be a major breakthrough in the field.
Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
Galantamine and memantine via the α7nACh and NMDA receptors can counteract the effects of kynurenic acid and enhance MMN and BDNF and future studies with the galantamine-memantine combination with KP metabolites, MMN, andBDNF as biomarkers are warranted.
Cognitive Enhancer Effects of Low Memantine Doses Are Facilitated by an Alpha7 Nicotinic Acetylcholine Receptor Agonist in Scopolamine-Induced Amnesia in Rats
The results suggest that memantine and PHA-543613 may exert their cognitive enhancer effects on the same target, possibly on the alpha7 nAChRs.
The Tyrosine Phosphatase STEP Is Involved in Age-Related Memory Decline


Update on the use of memantine in Alzheimer's disease.
An oversight of pharmacodynamics and pharmacokinetics of memantine is presented and published data concerning efficacy and safety in patients with AD are presented.
Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease
Pharmacokinetic and pharmacodynamic as well as ongoing observation studies support the concept of adjunctive therapy with memantine in patients with advanced moderate Alzheimer's disease currently treated with an established galantamine regimen.
Galantamine for Alzheimer's disease and mild cognitive impairment.
Prolong release / once daily formulation of galantamine at 16 - 24mg/d was found to have similar efficacy and side-effect profile as the equivalent twice-daily regime, and Galantamine's safety profile in AD is similar to that of other cholinesterase inhibitors with respect to cholinergically mediated gastrointestinal symptoms.
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI
In an interrupted trial with amnestic MCI subjects the combination of galantamine plus memantine were generally well tolerated and a cognitive benefit of a short-term combination treatment of galantsamine plus Memantine was observed, and cognitive decline occurred after discontinuation of Galantamine.
Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.
The current status on the pharmacology of galantamine is summarized, focusing on its effect on neurotransmitter release and pharmacological studies in animal models of psychiatric disorders.
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.
The results suggest that the effects of memantine treatment on AD brain include disease modification and prevention of synaptic dysfunction.
Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer's Disease
It is indicated that memantine improves hippocampus-based spatial learning in a transgenic mouse model of AD without producing nonspecific effects on locomotion/exploratory activity.
Memantine in moderate-to-severe Alzheimer's disease.
Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.
The Acetylcholinesterase Inhibitor Galantamine Inhibits d-Amphetamine-Induced Psychotic-Like Behavior in Cebus Monkeys
Galantamine was investigated for its ability to antagonize d-amphetamine-induced psychotic-like behavior in extrapyramidal side effects (EPS)-primed Cebus monkeys and the results indicate that AChE inhibitors have antipsychotic potentials and suggest that clinical trials investigating antipsychotics effects of A ChE inhibitors as monotherapy would be of interest.